The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders

Pharmacology and Toxicology

Volumn 80, Issue 4, 1997, Pages 159-166

  Gassen, M ^a   Youdim, M B H ^a  

^a B Rappaport Fam Med Sci Bldg   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE MESYLATE; EDETIC ACID DERIVATIVE; FLAVONOID; IRON; IRON CHELATE;

CELL DEATH; DEGENERATIVE DISEASE; HUMAN; IRON CHELATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0030891276     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1997.tb00390.x     Document Type: Review

References (77)

1. Andrew, R., D. G. Watson, S. A. Best, H. Midgey, H. Wenlong & R. K. H. Petty: The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls. Neurochem. Res. 1993, 18, 1175–1177.
2. Aoki, S., Y. Okada, K. Nishimura, A. J. Barkovich, B. O. Kjos, R. C. Brasch & D. Norman: Normal deposition of brain iron in childhood and adolescence: Magnetic resonance imaging at 1.5 T. Radiology 1989, 172, 381–385.
3. Beard, J. L., J. D. Connor & B. C. Jones: Brain iron: location and function. Prog. Food Nutr. Sci. 1993, 17, 183–221.
4. Bel, A., E. Martinod & P. Menasche: Cardioprotective effect of desferrioxamine. Acta haematol. 1996, 95, 63–65.
5. Ben‐Shachar, D., G. Eshel, P. Riederer & M. B. H. Youdim: Role of iron and iron chelation in dopaminergic‐induced neurodegeneration: implication for Parkinson's disease. Ann. Neurol. 1992, 32, (Suppl.), S105–S110.
6. Ben‐Shachar, D., J. P. M. Finberg & M. B. H. Youdim: Effect of iron chelation on dopamine D 2 receptors. J. Neurochem. 1985, 45, 999–1005.
7. Ben‐Shachar, D., E. Livne, I. Spanier, K. L. Leenders & M. B. H. Youdim: Typical and atypical neuroleptics induce alteration in blood‐brain barrier and brain 59 FeCl 3 uptake. J. Neurochem 1994, 62, 1112–1118.
8. Ben‐Shachar, D., E. Livne, I. Spanier, R. Zuk & M. B. H. Youdim: Iron modulates neuroleptic‐induced effects related to the dopaminergic system. Isr. J. Med. Sci. 1993, 29, 587–592.
9. Ben‐Shachar, D., P. Riederer & M. B. H. Youdim: Iron‐melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 1991, 57, 1609–1614.
10. Ben‐Shachar D. & M. B. H. Youdim: Selectivity of melanized nigrastriatal dopamine neurons to degeneration in Parlinson's disease may depend on iron‐melanin interaction. J. Neural Transm. 1990, 29, (Suppl.) 251–258.
11. Ben‐Shachar, D. & M. B. H. Youdim: Intranigral iron injection induces behavioral and biochemical “parkinsonism” in rats. J. Neurochem. 1991, 57, 2133–2135.
12. Benkovic, S. A. & J. R. Connor: Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain. J. Comparative Neurol. 1993, 338, 97–113.
13. Binder, R., J. A. Horowitz, J. P. Basilion, D. M. Koeller, R. D. Klausner & J. B. Harford: Evidence that the pathway of transferrin receptor mRNA degradation involves an endonucleolytic cleavage within the 3′ UTR and does not involve poly(A) tail shortening. EMBO J. 1994, 13, 1969–1980.
14. Blake, D. R., P. Winyard, J. Lunec, A. Williams, P. A. Good, S. J. Crewes, J. M. Gutteridge, D. Rowley, B. Halliwell & A. Cornish: Cerebral and ocular toxicity induced by desferrioxamine. Quart. J. Med. 1985, 56, 345–355.
15. Borel, M. J., S. H. Smith, D. E. Brigham & J. L. Beard: The impact of varying degrees of iron nutriture on several functional consequences of iron deficiency in rats. J. Nutr. 1991, 121, 729–736.
16. Connor, J. R. & S. A. Benkovic: Iron regulation in the brain: histochemical, biochemical and molecular considerations. Ann. Neurol. 1992, 32, (Suppl.), S51–S61.
17. Connor, J. R., B. S. Snyder, P. Arosio, D. A. Loeffler & P. LeWitt: A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 1995, 65, 717–724.
18. Connor, J. R., B. S. Snyder, J. L. Beard, R. E. Fine & E. J. Mufson: Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci. Res. 1992, 31, 327–335.
19. Crichton, R. R. & R. J. Ward: Structure and molecular biology of iron binding proteins and the regulation of “free” iron pools. In: Iron and human disease. Ed. R. B. Lauffer CRC Press, Inc., Boca Raton, FL, 1992, pp. 23–75.
20. Crowe, A. & E. H. Morgan: Effects of chelators on iron uptake and release by the brain in the rat. Neurochem. Res. 1994, 19, 71–76.
21. Dexter, D. T., A. Carayon, F. Javoy‐Agid, Y. Agid, F. R. Wells, S. E. Daniel, A. J. Lees, P. Jenner & C. D. Marsden: Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114, 1953–1975.
22. Dexter, D. T., P. Jenner, A. H. V. Schapira & C. D. Mardsen: Alterations in level of iron, ferritin and other trace metals in neurodegenerative disease affecting basal ganglia. Ann. Neurol. 1992, 32, 94–100.
23. Faucheux, B. A., M. T. Herrero, J. Villares, R. Levy, F. Javoy‐Agid, J. A. Obeso, J. J. Hauw, Y. Agid & E. C. Hirsch: Autoradiographic localization and density of [ 125 I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP‐lesioned monkeys. Brain Res. 1995a, 691, 115–124.
24. Faucheux, B. A., N. Nillesse, P. Damier, G. Spik, A. Mouatt‐Prigent, A. Pierce, B. Leveugle, N. Kubis, J. J. Hauw & Y. Agid: Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1995b, 92, 9603–9607.
25. Galey, J. B., J. Dumats, I. Beck, B. Fernandez & M. Hocquaux: N, N'‐bis‐dibenzyl ethylenediaminediacetic acid (DBED): a site‐specific hydroxyl radical scavenger acting as an “oxidative stress activatable” iron chelator in vitro. Free Radic. Res. 1995, 22, 67–86.
26. Gerlach, M., D. Ben‐Shachar, P. Riederer & M. B. H. Youdim: Altered brain metabolism of iron as a cause of neurodegenerative diseases J. Neurochem. 1994, 63, 793–807.
27. Glinka, Y., M. Gassen & M. B. H. Youdim: Iron and neurotransmitter function in brain. In: Metals and oxidative damage in neurological disorders. Ed. J. R. Connors Plenum Publishing Corp, New York, 1996.
28. Glinka, Y., K. F. Tipton & M. B. H. Youdim: Nature of inhibition of mitochondrial respiratory complex I by 6‐hydroxydopamine. J. Neurochem. 1996, 66, 2004–2010.
29. Gower, J. D., I. J. Ambrose, S. Manek, J. Bright, P. S. Dobbin, R. C. Hider, J. G. Goddard, M. S. Thorniley & C. J. Green: The effect of a synthetic hexadentate iron chelator (CP130) and desferrioxamine on rabbit kidneys exposed to cold and warm ischaemia. Agents Actions 1993, 40, 96–105.
30. Hall, E. D. & J. M. McCall: Lazaroids: potent inhibitors of iron‐dependent lipid peroxidation for neurodegenerative disorders. In: Iron in central nervous system disorders. Eds. P. Riederer & M. B. H. Youdim Springer‐Verlag, Wien, 1993, pp. 173–188.
31. Halliday, J. W. & J. W. Powell: Hereditary hemochromatosis and other diseases associated with iron overload. In: Iron and human disease. Ed. R. B. Lauffer CRC Press, Boca Raton, 1992, pp. 131–160.
32. Halliwell, B. & J. M. C. Gutteridge: Oxygen radicals and the nervous system. Trends Neurol. Sci. 1985, 8, 22–29.
33. Halliwell, B., J. M. Gutteridge & D. Blake: Metal ions and oxygen radical reactions in human inflammatory joint disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 1985, 311, 659–671.
34. Harris, L. R., M. H. Cake & D. J. Macey: Iron release from ferritin and its sensitivity to superoxide ions differs among vertebrates. Biochem. J. 1994, 301, 385–389.
35. Hasinoff, B. B., S. Venkataram, M. Singh & T. I. Kuschak: Metabolism of the cardioprotective agents dexrazoxane (ICRF‐187) and levrazoxane (ICRF‐186) by the isolated hepatocyte. Xenobiotica 1994, 24, 977–987.
36. Hermes‐Lima, M., R. F. Castilho, A. R. Meinicke & A. E. Vercesi: Characteristics of Fe(II)ATP complex‐induced damage to the rat liver mitochondrial membrane. Mol. Cell Biochem. 1995, 145, 53–60.
37. Hershko, C.: Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin. Haematol. 1994, 7, 965–1000.
38. Hershko, C., G. Link, M. Tzahor & A. Pinson: The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk. Lymphoma 1993, 11, 207–214.
39. Hershko, C., A. Pinson & G. Link: Prevention of anthracycline cardiotoxicity by iron chelation. Acta haematol. 1996, 95, 87–92.
40. Hider, R. C., R. Choudhury, B. L. Rai, L. S. Dehkordi & S. Singh: Design of orally active iron chelators. Acta haematol. 1996, 95, 6–12.
41. Jellinger, K., L. Linert, E. Kienzl, E. Herlinger & M. B. Youdim: Chemical evidence for 6‐hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J. Neural Transm. 1995, 46, (Suppl.) 293–310.
42. Kozlov, A. V., A. Bini, D. Gallesi, F. Giovannini, A. Iannone, A. Masini, E. Meletti & A. Tomasi: ‘ Free’ iron, as detected by electron paramagnetic resonance spectroscopy, increases unequally in different tissues during dietary iron overload in the rat. Biometals 1996, 9, 98–103.
43. Kukielka, E. & A. I. Cederbaum: Ferritin stimulation of hydroxyl radical production by rat liver nuclei. Arch. Biochem. Biophys. 1994, 308, 70–77.
44. Leenders, K. L., A. Antonini, R. Schwarzbach, P. Smith‐Jones, H. Reist, D. Ben‐Shachar, M. Youdim & V. Henn: Blood to brain iron uptake in one rhesus monkey using [Fe‐52]‐citrate and positron emission tomography (PET): influence of haloperidol. J. Neural Transm. 1994, 43, (Suppl.) 123–132.
45. Lipton, S. A., D. J. Singel & A. Moser: Neuroprotective and neuro‐destructive effects of nitric oxide and redox congeners. Ann. N. Y. Acad. Sci. 1994, 738, 382–387.
46. Loeffler, D. A., J. R. Connor, P. L. Juneau, B. S. Snyder, L. Kanaley, A. J. DeMaggio, H. Nguyen, C. M. Brickman & P. A. LeWitt: Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 1995, 65, 710–724.
47. Martins, E. A., R. L. Robalinho & R. Meneghini: Oxidative stress induces activation of a cytosolic protein responsible for control of iron uptake. Arch. Biochem. Biophys. 1995, 316, 128–134.
48. Marx, J. J. & B. S. van Asbeck: Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen‐radical‐mediated tissue damage. Acta haematol. 1996, 95, 49–62.
49. Mash, D. C., J. Pablo, B. E. Buck, J. Sanchez‐Ramos & W. J. Weiner: Distribution and number of transferrin receptors in Parkinson's disease and in MPTP‐treated mice. Exp. Neurol. 1991, 114, 73–81.
50. Minotti, G. & S. D. Aust: The role of iron in the initiation of lipid peroxidation. Chem. Phys. Lipids 1987, 44, 191–208.
51. Morel, I., J. Cillard, G. Lescoat, O. Sergent, N. Pasdeloup, A. Z. Ocaktan, M. A. Abdallah, P. Brissot & P. Cillard: Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid‐4‐ones in iron‐loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine. Free Radic. Biol. Med. 1992, 13, 499–508.
52. Morel, I., G. Lescoat, P. Cogrel, O. Sergent, N. Pasdeloup, P. Brissot, P. Cillard & J. Cillard: Antioxidant and iron‐chelating activities of the flavonoids catechin, quercetin and diosmetin on iron‐loaded rat hepatocyte cultures. Biochem. Pharmacol. 1993, 45, 13–19.
53. Morel, I., O. Sergent, P. Cogrel, G. Lescoat, N. Pasdeloup, P. Brissot, P. Cillard & J. Cillard: EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid‐4‐one in iron‐loaded hepatocyte culture: comparison with that of desferrioxamine. Free Radic. Biol. Med. 1995, 18, 303–310.
54. Morris, C. M., J. M. Kerwin & J. A. Edwardson: Non‐haem iron histochemistry of the normal and Alzheimer's disease hippocampus. Neurodegeneration 1994, 3, 267–275.
55. Nielsen, J. E., L. N. Jensen & K. Krabbe: Hereditary haemo‐chromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J. Neurol. Neurosurg. Psych. 1995, 59, 318–321.
56. Olanow, C. W. & M. B. H. Youdim: Iron and neurodegeneration: prospects for neuroprotection. In: Neurodegeneration and neuroprotection in Parkinson's disease. Eds. C. W. Olanow, P. Jenner & M. B. H. Youdim Academic Press, London, 1996, pp. 55–67.
57. Olivieri, N. F.: Long‐term therapy with deferiprone. Acta haematol. 1996, 95, 37–48.
58. Pantopoulos, K. & M. W. Hentze: Nitric oxide signaling to iron regulatory protein: Direct control of ferritin mRNA translation and transferrin receptor mRNA stability in transfected fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 1995a, 92, 1267–1271.
59. Pantopoulos, K. & M. W. Hentze: Rapid responses to oxidative stress mediated by iron regulatory protein. EMBO J. 1995b, 14, 2917–2924.
60. Riederer, P., A. Dirr, M. Goetz, E. Sofic, K. Jellinger & M. B. H. Youdim: Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann. Neurol. 1992, 32, (Suppl.), S101–S104.
61. Riederer, P., W. D. Rausch & B. Schmidt: Biochemical fundaments of Parkinson's disease. Mt. Sinai J. Med. 1988, 55, 21–29.
62. Riederer, P., E. Sofic, W. D. Rausch, B. Schmidt, G. P. Reynolds, K. Jellinger & M. B. H. Youdim: Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 1989, 52, 512–520.
63. Rossi, M. A., M. Curzio, C. DiMauro, F. Fidale, A. Garramone, H. Esterbauer, M. Torrielli & M. U. Dianzani: Experimental studies on the mechanism of action of 4‐hydroxy‐2,3‐trans‐non‐enal, a lipid peroxidation product displaying chemotactic activity toward rat neutrophils. Cell Biochem. Funct. 1991, 9, 163–170.
64. Shoham, S., E. Wertman & R. P. Ebstein: Iron accumulation in the rat basal ganglia after excitatory amino acid injections‐dissociation from neuronal loss. Exp. Neurol. 1992, 118, 227–241.
65. Siimes, M. A., C. Refino & P. R. Dallman: Manifestation of iron deficiency at various levels of dietary iron intake. Amer. J. Clin. Nutr. 1980, 33, 570–574.
66. Singh, V., S. Ahmad & G. S. Rao: Prooxidant and antioxidant properties of iron‐hydroquinone and iron‐1,2,4‐benzenetriol complex. Implications for benzene toxicity. Toxicology 1994, 89, 25–33.
67. Sofic, E., W. Paulus, K. Jellinger, P. Riederer & M. B. H. Youdim: Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 1991, 56, 978–982.
68. Thomas, L. O., O. B. Boyko, D. C. Anthony & P. C. Burger: MR detection of brain iron. AJNR. Amer. J. Neuroradiol. 1993, 14, 1043–1048.
69. Trenam, C. W., P. G. Winyard, C. J. Morris & D. R. Blake: Iron promoted oxidative damage in rheumatic diseases. In: Iron and human disease. Ed. R. B. Lauffer CRC Press, Boca Raton, 1992, pp. 395–418.
70. van der Wal, N. A., J. F. van Oirschot, A. van Dijk, J. Verhoef & B. S. van Asbeck: Mechanism of protection of alveolar type II cells against paraquat‐induced cytotoxicity by desferrioxamine. Biochem. Pharmacol. 1990, 39, 1665–1671.
71. Xiao, G., D. van der Helm, R. C. Hider & B. L. Rai: Molecular modeling studies of a ferric hexadentate 3‐hydroxy‐2(1H)‐pyridone complex and an analog by molecular mechanics, molecular dynamics, and free energy perturbation simulations. J. Phys. Chem. 1996, 100, 2345–2352.
72. Yajima, N., H. Hiraishi & T. Harada: Protection of cultured rat gastric cells against oxidant stress by iron chelation. Role of lipid peroxidation. Dig. Dis. Sci. 1995, 40, 879–886.
73. Yoritaka, A., N. Hattori, K. Uchida, M. Tanaka, E. R. Stadtman & Y. Mizuno: Immunohistochemical detection of 4‐hydroxynonenal protein adducts in Parkinson's disease. Proc. Natl. Acad. Sci. USA 1996, 93, 2696–2701.
74. Yoshida, T., M. Tanaka, A. Sotomatsu & S. Hirai: Activated microglia cause superoxide‐mediated release of iron from ferritin. Neurosci. Lett. 1995, 190, 21–24.
75. Youdim, M. B. H., D. Ben‐Shachar & P. Riederer: Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur. Neurol. 1991, 31, (Suppl.), 34–40.
76. Youdim, M. B. H., D. Ben‐Shachar & P. Riederer: The possible role of iron in the ethiopathology of Parkinson's disease. Movement Disorders 1993, 8, 1–12.
77. Youdim, M. B. H., D. Ben‐Shachar & P. Riederer: The enigma of neuromelanin in Parkinson's disease substantia nigra. J. Neural Transm. 1994, 43, (Suppl.) 113–122.